预约演示
更新于：2025-09-05
Betamethasone Sodium Phosphate
磷酸钠倍他米松
更新于：2025-09-05
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-LWCNAHDDSA-N |
CAS号151-73-5 |
关联
30
项与 磷酸钠倍他米松 相关的临床试验NCT07078786
Comparison of Effect of Antenatal Dexamethasone Versus Betamethasone on Antepartum Cardiactocography
ChiCTR2500096518
Randomized controlled study of improving preterm birth outcomes by reducing prenatal corticosteroid exposure
ChiCTR2400090847
The value of CT-FFR in the diagnosis and treatment of patients with NSTE-ACS: A multicenter, prospective, randomized controlled study(TARGET2 Trial)
100 项与 磷酸钠倍他米松 相关的临床结果
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的转化医学
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的专利（医药）
登录后查看更多信息
1,146
项与 磷酸钠倍他米松 相关的文献（医药）2025-11-01FOOD CHEMISTRY
Study on the influential mechanism of catechin on the volatility of aroma compounds in ethanol-water solution by instrumental analysis and theoretical calculation
Article
作者: Shi, Jie ; Zhang, Jinglin ; Li, Hehe ; Zhao, Dongrui ; Xu, Yin ; Huang, Mingquan ; Li, Guoxiang ; Wu, Jihong ; Liu, Hongqin
In this work, the influential mechanism of catechin on the volatilities of aroma compounds (ACs) in ethanol-water solution was investigated using solid-phase microextraction and gas chromatography mass spectrometry (SPME-GC/MS), combined with thermodynamic analysis, and theoretical calculations. The volatilities of a series of esters, pyrazines, and phenolic compounds with similar structures in 46 % ethanol solution at different concentrations of catechin were detected by SPME-GC/MS. The volatilities of ACs with less methyl numbers were suppressed by catechin. As the increase of methyls in the molecular, their volatilities tended to be promoted. As the increase of concentration of catechin, the volatilities of ACs were gradually promoted. Thermodynamic analysis showed that the hydrophobic interaction was the main interaction between ACs and catechin. Theoretical calculations showed that the catechin affected the volatilities of ACs by changing the micro ethanol concentration (MEC) around the aroma molecular in ethanol-water solution.
2025-10-01CARBOHYDRATE POLYMERS
Graft copolymerization of bio-based β-farnesene and n-butyl acrylate onto modified anionic cassava starch via emulsifier-free emulsion polymerization for sustainable adhesives
Article
作者: Oliveira, Maurício P ; Rodrigues, Lina D A ; Guerrini, Lilia M
In this study, bio-based β-farnesene (Far) and modified anionic cassava starch (ACS) were chosen as renewable alternatives to replace traditional non-renewable monomers in emulsifier-free emulsion polymerization for the development of bio-based materials. Graft copolymerization of Far and n-butyl acrylate (BA) onto ACS was carried out in a semi-batch emulsion polymerization, using 7.0 wt% of ACS and varying Far/BA ratios (100:0, 80:20, 70:30, 60:40, 50:50 and 0:100 wt%). By adjusting the Far/BA ratio, the final properties of the polymer latexes were effectively modulated. The use of ACS modified in situ proved colloidal stability of the latexes, with hydrodynamic diameter ranging from 150 to 200 nm and overall monomer conversion of 90-99 % for formulations containing up to 50 wt% Far. The gel content of poly(Far-co-BA)-g-ACS was significantly higher, while elongation at break decreased with increasing Far content. The glass transition temperature (Tg) of poly(Far-co-BA)-g-ACS ranged from -34 to +3.2 °C, which makes them attractive for a wide range of adhesive applications. The final polymers exhibited distinct adhesive performances, providing a strategic approach to tailoring end-use properties for specific applications. Furthermore, the use of in situ modified anionic cassava starch (ACS) provides valuable insights for the development of bio-based polymer materials under industrially relevant conditions.
2025-09-01EARLY HUMAN DEVELOPMENT
Antenatal corticosteroid exposure and neonatal outcomes in term infants
Article
作者: Chung, Hao-Wei ; Liang, Fu-Wen ; Yu, Chia-Hung ; Huang, Chiao-Yun
BACKGROUND:
Antenatal corticosteroids (ACS) are widely used to mitigate respiratory distress in preterm infants. Although the benefits of ACS in preterm births are well established, less is known about the short-term neonatal risks when ACS is administered during pregnancies that result in term delivery. Additionally, the impact of gestational age at the time of ACS exposure in this population remains unclear.
AIM:
To evaluate the association between ACS exposure and short-term neonatal outcomes in term-born singleton infants, and further assess outcome variation by gestational age at exposure.
METHOD:
This retrospective, population-based cohort study used data from the Taiwan Maternal and Child Health Database and the National Health Insurance Research Database to compare term-born singleton infants exposed to ACS for threatened preterm labor with those unexposed, whose mothers had no diagnosis of preterm labor and no recorded ACS administration. Neonatal outcomes were analyzed using multivariable logistic regression.
RESULTS:
Among 800,024 term births, 5577 (0.6 %) were exposed to ACS due to preterm labor. ACS-exposed infants had higher rates of SGA, CPAP, oxygen use, NICU admission, sepsis, hypoglycemia, TTNB, and jaundice (P < 0.001). Adjusted analyses revealed higher odds of SGA (aOR 1.30; 95 % CI 1.20-1.41), NICU admission (aOR 1.16; 95 % CI 0.99-1.36), and hyperbilirubinemia (aOR 1.49; 95 % CI 1.38-1.61) in the exposed group. Exposure between 28 and 33 weeks was associated with increased odds of oxygen therapy (aOR 1.42; 95 % CI 1.21-1.67) and TTNB (aOR 1.40; 95 % CI 1.00-1.94).
CONCLUSION:
ACS exposure is associated with increased risks of short-term neonatal complications among term-born infants, especially when exposure between 28 and 33 weeks' gestation. Even when pregnancies end in term delivery, ACS exposure may still increase neonatal morbidity risk.
100 项与 磷酸钠倍他米松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 溃疡性结肠炎 | 日本 | 1992-03-13 | |
| 克罗恩病 | 日本 | 1992-03-13 | |
| 睑缘炎 | 日本 | 1985-11-20 | |
| 结膜炎 | 日本 | 1985-11-20 | |
| 角膜炎 | 日本 | 1985-11-20 | |
| 耳炎 | 日本 | 1985-11-20 | |
| 炎症 | 美国 | 1974-12-31 | |
| 胶原蛋白疾病 | 日本 | 1973-01-31 | |
| 内分泌系统疾病 | 日本 | 1973-01-31 | |
| 心脏衰竭 | 日本 | 1973-01-31 | |
| 肾病综合征 | 日本 | 1973-01-31 | |
| 类风湿关节炎 | 日本 | 1973-01-31 | |
| 眼部炎症 | 日本 | 1964-10-07 | |
| 外耳炎 | 日本 | 1964-10-07 | |
| 中耳炎 | 日本 | 1964-10-07 | |
| 过敏性鼻炎 | 日本 | 1964-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 139 | (SURF-200 (0.02% Betamethasone Sodium Phosphate in Vehicle)) | 鑰糧觸壓窪願觸繭獵窪 = 鬱窪顧積繭製餘衊鹽繭 遞淵鬱構襯糧顧築觸艱 (鬱餘憲鏇範積網積壓觸, 憲齋構顧壓醖廠夢範構 ~ 醖艱築製醖範糧襯鬱鹽) 更多 | - | 2025-06-04 | ||
(SURF-200 (0.04% Betamethasone Sodium Phosphate in Vehicle)) | 鑰糧觸壓窪願觸繭獵窪 = 願蓋鏇醖繭餘醖糧餘膚 遞淵鬱構襯糧顧築觸艱 (鬱餘憲鏇範積網積壓觸, 鹽鬱衊夢選鑰獵窪窪襯 ~ 鬱餘襯繭繭蓋醖鬱鬱鏇) 更多 | ||||||
临床2期 | 1 | (Bupivacaine Hydrochloride and Betamethasone Sodium Phosphate) | 艱憲餘簾鹽獵齋齋窪窪(艱構鬱廠壓觸顧襯衊餘) = 廠獵構膚齋艱糧網衊構 鏇選膚製簾選鹹窪願構 (築簾範獵壓齋夢簾鏇鏇, 蓋築獵齋獵顧構鹽醖糧 ~ 淵壓範廠衊淵獵簾構壓) 更多 | - | 2020-11-02 | ||
(Bupivacaine Hydrochloride) | 艱憲餘簾鹽獵齋齋窪窪(艱構鬱廠壓觸顧襯衊餘) = 鬱製窪鏇鏇膚醖醖淵築 鏇選膚製簾選鹹窪願構 (築簾範獵壓齋夢簾鏇鏇, 壓鏇繭齋遞選醖夢繭鑰 ~ 襯憲糧網鏇築鏇淵選淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用